Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in a report released on Friday,Zacks.com reports. A number of other equities ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure ...

29,885 people played the daily Crossword recently. Can you solve it faster than others?29,885 people played the daily Crossword recently. Can you solve it faster than others? If I Could Buy Only 1 ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma. Looking at options history for Verona Pharma (NASDAQ:VRNA) we detected 14 trades. If we consider the ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 ...